... the trial info still dates as of Sept 2017 (last update, cf. https://clinicaltrials.gov/ct2/show/NCT02531425) and has some primary completion date of December 2017 + enrollment of max. 10 participants. They first spoke of "to date five patients" in January. So it could be, if they ran the trial a bit longer. However, Oncosec needs an accessible cancer lesion, this is why only some of those very ill patients are eligible at all, cf. eligibility criteria:
This is actually the much bigger question. The current delivery device has "adjustable needles, 1 to 15 mm" (company presentation), any cancer deeper than that is currently out of reach.
IMHO besides Keynote-695 (melanoma) the next most interesting thing will be their coming delivery device (meant to reach deeper) and if it 'delivers' (efficacy, but also pain?).
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.